对于失败的单心室生理学而言,心脏再同步治疗
Yuji Tominaga1, Heima Sakaguchi2, Masashi Takeshita1
1Department of Pediatric Cardiovascular Surgery, National Cerebral and Cardiovascular Centre, Osaka, Japan.
概括
心脏再同步疗法改善了心脏功能和心力衰竭症状在单心室患者与失同. 这种疗法在这个复杂的患者群体中有望改善结果.
科学领域:
- 心脏病学 心脏病学
- 儿童心脏病学 儿童心脏病学
- 遗传性心脏病是一种先天性心脏病.
背景情况:
- 单心室生理学在管理心力衰竭和心室失调时提出了独特的挑战.
- 心室失调导致单心室患者的不良结果,加剧心力衰竭症状.
研究的目的:
- 评估心脏再同步治疗 (CRT) 在单心室生理学,心力衰竭和心室失同症患者的中期疗效.
- 评估CRT对血液动力学参数,功能状态和这一队列的长期生存的影响.
主要方法:
- 在2010年至2024年期间接受CRT的单心室患者的回顾性审查.
- 由QRS持续时间 (≥130毫秒) 和机械评估定义的异步;基于血液动力学改善的CRT指示.
- 患者被分为G组 (后双向格伦) 和F组 (后方丹完成);分析包括生存率,功能类和器官功能.
主要成果:
- 在手术后一年,CRT改善了全身心室喷射率 (G组: 30-40%,F组: 30-53%) 和心脏指数.
- 五年生存率很高 (G组的89%,F组的82%);G组的Fontan完成率在5年内为76%
- 组F显示大脑尿素水平改善,肝功能稳定,没有报告的蛋白质损失肠病.
结论:
- 心脏再同步疗法有效地增强全身心室功能,并减轻单心室患者的心力衰竭症状.
- 对于心脏衰竭和心室失调的单心室患者来说,CRT是一种潜在的有价值的治疗策略,可以改善他们的生活质量和预后.
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
634
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
01:29Cardiomyopathy V: Interprofessional Care
506
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
506
01:22Heart Failure VI: Adjunct Therapies
430
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
430
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
628
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
628
01:30Heart Failure V: Medical Management
392
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
392
01:25Mitral Regurgitation III: Medical Management
417
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
417